Therapeutic Lowering of Lipoprotein(a): A Role for Pharmacogenetics?

Affiliations

¹ From the Department of Biochemistry (M.B.B.) and Robarts Research Institute (M.L.K.), Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
² From the Department of Biochemistry (M.B.B.) and Robarts Research Institute (M.L.K.), Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada. mlk@robarts.ca.

Editorial

Michael B Boffa et al. Circ Genom Precis Med. 2018 Feb.

. 2018 Feb;11(2):e002052.

doi: 10.1161/CIRCGEN.118.002052.

¹ From the Department of Biochemistry (M.B.B.) and Robarts Research Institute (M.L.K.), Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
² From the Department of Biochemistry (M.B.B.) and Robarts Research Institute (M.L.K.), Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada. mlk@robarts.ca.

No abstract available

Keywords: Editorials; cardiovascular diseases; genetics; lipoprotein(a); naicin; pharmacogenetics; risk factors.

Comment on

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J; HPS2-THRIVE Collaborative Group. Parish S, et al. Circ Genom Precis Med. 2018 Feb;11(2):e001696. doi: 10.1161/CIRCGEN.117.001696. Circ Genom Precis Med. 2018. PMID: 29449329 Free PMC article. Clinical Trial.